Hedera Dx Secures €15 Million Series A

Hedera Dx Raises €15M Series A to Expand Access to Precision Oncology Across Europe

Hedera Dx, a Vaud-Based techbio company advancing precision cancer care, announced the successful close of a €15 million Series A financing round. The round was led by Vsquared Ventures, with new investor Tesi joining and strong support from existing backers including Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.

This funding milestone will accelerate Hedera Dx’s mission to eliminate the systemic barriers that prevent cancer patients from accessing targeted therapies. Founded by leaders who previously scaled top European genomics and healthcare companies — including Blueprint Genetics, Roche, and Molecular Health — the company aims to become a global force in next-generation oncology diagnostics.

Transforming Cancer Diagnostics in Europe

Outside the U.S., cancer diagnostics must often be performed within hospital laboratories, rather than centralized labs. Responding to this challenge, Hedera Dx has developed liquid biopsy solutions that enable hospital labs to perform cost-effective, blood-based cancer testing in-house. These tests offer high quality and affordability, and are already being used in 11 European countries.

Hedera Dx is rapidly establishing itself as Europe’s leading platform for precision oncology. Its AI-native solution not only delivers advanced molecular profiling to guide physicians’ treatment decisions but also generates real-world, patient-centric insights to support the development of future oncology therapies.

“At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician — globally,” said Tommi Lehtonen, CEO and co-founder. “There are many personalized cancer treatments available, but far too many patients can’t access them. Our technology empowers hospital labs to change that.”

Backed by Investors to Redefine Oncology Care

“Hedera Dx is addressing a critical gap in oncology care,” said Dr. Lise Rechsteiner, General Partner at Vsquared Ventures. “Their in-house diagnostics model increases patient access to testing and enables more effective treatment. Combined with their real-world data capabilities, Hedera is poised to lead precision oncology in healthcare systems beyond the U.S.”

“We’re not just improving access,” added Dr. Christian Meisel, CMO and co-founder. “We’re building a platform that delivers actionable real-world insights and accelerates the development of life-saving therapies.”

With the new funding, Hedera Dx will continue expanding its commercial footprint and enhance its real-world data infrastructure, strengthening its position in the global oncology market and bringing precision medicine to more patients across Europe and beyond.

➡️ Source: Hedera Dx | 📸 L-R: Damien Lapray (CCO), Christian Meisel (CMO), Tommi Lehtonen (CEO) ©Hedera Dx